Hosking Partners LLP Sells 9,584 Shares of Elevance Health, Inc. $ELV

Hosking Partners LLP lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 6.4% during the third quarter, Holdings Channel reports. The firm owned 140,427 shares of the company’s stock after selling 9,584 shares during the period. Elevance Health makes up approximately 1.9% of Hosking Partners LLP’s investment portfolio, making the stock its 15th largest position. Hosking Partners LLP’s holdings in Elevance Health were worth $54,601,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of ELV. Field & Main Bank boosted its holdings in shares of Elevance Health by 1.3% in the 2nd quarter. Field & Main Bank now owns 1,883 shares of the company’s stock valued at $728,000 after buying an additional 25 shares in the last quarter. Tranquilli Financial Advisor LLC grew its position in shares of Elevance Health by 1.3% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company’s stock valued at $805,000 after buying an additional 26 shares during the last quarter. Mather Group LLC. raised its stake in Elevance Health by 3.5% during the 3rd quarter. Mather Group LLC. now owns 766 shares of the company’s stock worth $298,000 after acquiring an additional 26 shares in the last quarter. 55 North Private Wealth LLC raised its stake in Elevance Health by 4.5% during the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company’s stock worth $233,000 after acquiring an additional 26 shares in the last quarter. Finally, WealthCollab LLC raised its stake in Elevance Health by 42.2% during the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after acquiring an additional 27 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 1.1%

NYSE ELV opened at $435.26 on Thursday. The firm’s fifty day moving average is $406.59 and its two-hundred day moving average is $389.52. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52. The firm has a market cap of $94.39 billion, a PE ratio of 14.98, a P/E/G ratio of 2.29 and a beta of 0.70.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The business had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. During the same quarter in the prior year, the firm earned $6.03 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. Analysts expect that Elevance Health, Inc. will post 27.20 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is currently 30.58%.

Analyst Ratings Changes

ELV has been the subject of a number of research reports. TD Cowen boosted their price target on shares of Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Wells Fargo & Company dropped their price objective on Elevance Health from $492.00 to $473.00 and set an “overweight” rating on the stock in a report on Thursday, July 16th. Leerink Partners lifted their target price on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research report on Friday, July 17th. The Goldman Sachs Group reiterated a “neutral” rating and set a $395.00 target price on shares of Elevance Health in a research report on Thursday, July 16th. Finally, Robert W. Baird upped their target price on Elevance Health from $331.00 to $393.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and a consensus target price of $441.71.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings were $6.99 per share versus the roughly $4.66–$4.71 consensus estimate, while revenue reached $50.44 billion, above expectations of about $49.22 billion. Earnings also increased from $6.03 per share a year earlier. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: 2026 outlook was raised: Management lifted its underlying earnings baseline to at least $26.75 per share, citing disciplined expense management and better medical-cost performance. Elevance also expects at least 12% adjusted EPS growth in 2027 from the higher earnings base. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon remained a growth driver: Strength in the services business helped offset pressure elsewhere, supporting management’s confidence in future growth. Elevance named Jeff Park president of Carelon, effective December 1, to lead its next expansion phase. Elevance Health Names Jeff Park President of Carelon
• Neutral Sentiment: Elevance declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%. The payout supports shareholder returns but is unlikely to be the primary near-term trading catalyst.
• Negative Sentiment: Membership pressure remains a concern: The earnings beat occurred despite declining medical membership, increasing investor focus on enrollment trends and the company’s ability to sustain growth.
• Negative Sentiment: Although cost management improved, Elevance operates on a thin net margin, and continued medical-cost inflation or weaker enrollment could limit the benefit of the raised forecast. The shares have also recently traded near a 52-week high, potentially increasing profit-taking risk.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.